USA flag logo/image

An Official Website of the United States Government

Ultrasound mediated targeted therapy for kidney disease

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93703
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
DK083142
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
TARGESON, LLC
850 CARLINS WAY CHARLOTTESVILLE, VA 22903-7666
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Ultrasound mediated targeted therapy for kidney disease
Agency: HHS
Contract: 1R43DK083142-01
Award Amount: $166,046.00
 

Abstract:

DESCRIPTION (provided by applicant): Antibodies can be used diagnostically as ligands for molecular imaging, and also as therapeutic to neutralize factors involved in the development of kidney disease. However, the systemic administration of many relevant antibodies may lead to serious side-effects in other organs. To minimize systemic exposure and concentrate efficacy to the target organ we propose to develop a novel acoustically activated therapeutic antibody delivery vehicle for local treatment of experi mental diabetic nephropathy. Simultaneous targeted accumulation and therapy is accomplished by utilizing antibodies able to 1) mediate targeted microbubble adhesion to sites of inflammation and fibrosis, and 2) produce therapeutic effects by neutralizing m olecular targets. Microbubble ultrasound contrast agents will be targeted to relevant molecular markers of kidney disease by monoclonal antibodies immobilized to the surface of the agent. Antibodies against two targets will be investigated: P-selectin and TGF-beta. Antibody-bearing microbubbles will be administered intravenously and accumulate at sites of intravascular expression of TGF-beta and P-selectin. Low-power (non-destructive) contrast ultrasound imaging will be used to visualize and quantify retent ion of antibody-coated microbubbles within the kidney. Antibodies will then be released from the microbubbles by high power ultrasound, via ultrasound mediated microbubble destruction. This method has shown efficacy for delivering reporter genes to perivas cular tissue in mice and rats, although targeted accumulation of the therapeutic microbubble at the target site has not been demonstrated. We propose quantify the payload of antibody-bearing microbubbles and verify targeted adhesion to recombinant target p roteins. The ability of these microbubbles to selectively deliver antibodies to renal tissue, and specifically glomeruli, will be examined using immunohistochemistry and contrast-enhanced ultrasound imaging in a mouse model of diabetic kidney disease. This project will result in the development of a novel and efficient targeted antibody delivery tool for pre-clinical research. Additionally, this work has the potential to translate into a clinically viable method of treatment for diabetic nephropathy. Public Health Relevance: Antibody therapy offers a treatment modality for advanced kidney disease, for which only symptomatic treatment is currently available. Ultrasound-mediated microbubble antibody delivery is a safe, non-viral, non- invasive and high- efficiency method of drug-delivery. This approach would reduce the amount of antibody needed and target the site of injury, while the specific retention of microbubbles in the kidney would allow for monitoring the progression of diabetic kidney disease usi ng ultrasound imaging.

Principal Investigator:

Joshua J. Rychak
4349770062
JOSHUA.RYCHAK@TARGESON.COM

Business Contact:

Joshua Rychak
joshua.rychak@targeson.com
Small Business Information at Submission:

TARGESON, LLC
TARGESON, LLC 325 Barracks Hill Road CHARLOTTESVILLE, VA 22901

EIN/Tax ID: 127006058
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No